Background Crizotinib may be the initial tyrosine kinase inhibitor approved for the treating anaplastic lymphoma kinase (inhibitor. treatment of NSCLC. In the ALUR trial, alectinib significantly improved effectiveness versus regular chemotherapy in positive NSCLC individuals who have been resistant or intolerant to crizotinib.7 In the ALEX trial, alectinib showed first-class effectiveness and lower toxicity in… Continue reading Background Crizotinib may be the initial tyrosine kinase inhibitor approved for the treating anaplastic lymphoma kinase (inhibitor